文献速递免疫规划传染病防控与疫情报告

编码Pvs25的环状RNA疫苗诱导阻断间日疟原虫传播的抗体

Circular RNA vaccines encoding Pvs25 induce antibodies that block Plasmodium vivax transmission.
PubMed 文献 · Vaccine · 2026-10-08

该研究开发了两种编码Pvs25的环状RNA-LNP疫苗(野生型及MITD融合型),并在小鼠中与线性核苷修饰mRNA-LNP疫苗比较免疫原性和功能活性。单次免疫即可诱导可检测的Pvs25特异性抗体,加强免疫大幅提高抗体滴度并完全抑制蚊体内间日疟原虫发育,两种疫苗均诱导抗体分泌细胞和细胞因子反应。

要点

  • 环状RNA Pvs25疫苗单次免疫诱导抗体,加强后完全阻断蚊体内疟原虫发育。
  • 环状RNA与线性mRNA疫苗均诱导Pvs25特异性抗体分泌细胞和细胞因子反应。
  • 环状RNA平台有望用于疟疾疫苗开发,支持进一步非人灵长类评估。

核心结论

  • 环状RNA编码Pvs25疫苗在小鼠中诱导强效传播阻断免疫,与线性mRNA疫苗类似。

研究设计与样本

  • 研究在小鼠中评估两种环状RNA-LNP疫苗(野生型Pvs25和Pvs25-MITD融合)与线性核苷修饰mRNA-LNP疫苗的免疫原性和功能活性。

主要发现

  • 单次免疫后,环状RNA或线性mRNA Pvs25疫苗均诱导可检测的Pvs25特异性抗体。
  • 加强免疫大幅提高抗体滴度,并完全抑制蚊体内间日疟原虫发育。
  • 两种疫苗均诱导强效Pvs25特异性抗体分泌细胞反应和产生细胞因子的细胞反应。

临床怎么用

  • 环状RNA可作为疟疾传播阻断疫苗的候选平台,支持进一步非人灵长类评估。

局限性

  • 研究仅在小鼠中进行,尚未在非人灵长类或人体验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Plasmodium vivax is a major malaria parasite that causes acute illness in millions of people each year. Transmission-blocking vaccines (TBVs) could contribute substantially to malaria elimination, although none has yet been approved. We previously demonstrated that a nucleoside-modified mRNA-lipid nanoparticle (mRNA-LNP) vaccine targeting Pvs25, a leading P. vivax TBV antigen, elicited potent and durable transmission-blocking immunity in mice. Emerging evidence suggests that circular RNA (circRNA) may enhance RNA stability, prolong antigen expression, and potentially reduce manufacturing costs compared with conventional linear mRNA. We therefore developed and evaluated two circular Pvs25 RNA-LNP vaccines: one encoding wild-type Pvs25 and another encoding Pvs25 fused to the MHC class I trafficking domain (MITD). Their immunogenicity and functional activity were compared with those of a linear nucleoside-modified Pvs25 mRNA-LNP vaccine. In mice, a single immunization with either the circular RNA or linear mRNA Pvs25 vaccine induced detectable Pvs25-specific antibodies, while booster immunization substantially increased antibody titers and resulted in complete inhibition of P. vivax development in mosquitoes. Both vaccines also elicited robust Pvs25-specific antibody-secreting cell response and cytokine-producing cellular responses. Together, these findings demonstrate the potential of circRNA as a platform for malaria vaccine development and support further evaluation in non-human primates.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kunkeaw N, Nguitragool W, Thosapornvichai T, et al. Circular RNA vaccines encoding Pvs25 induce antibodies that block Plasmodium vivax transmission. Vaccine. 2026. PMID: 42849225. doi:10.1016/j.vaccine.2026.129221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。